- Previous Close
10.03 - Open
10.08 - Bid 11.12 x 600
- Ask 11.19 x 600
- Day's Range
10.03 - 11.81 - 52 Week Range
5.71 - 16.99 - Volume
3,295,502 - Avg. Volume
1,234,885 - Market Cap (intraday)
940.815M - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
-- - EPS (TTM)
-1.58 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.00
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
www.liquidia.comRecent News: LQDA
View More
Performance Overview: LQDA
Trailing total returns as of 10/7/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LQDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LQDA
View MoreValuation Measures
Market Cap
846.31M
Enterprise Value
716.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
47.71
Price/Book (mrq)
13.49
Enterprise Value/Revenue
48.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.69%
Return on Equity (ttm)
-181.73%
Revenue (ttm)
14.84M
Net Income Avi to Common (ttm)
-112.11M
Diluted EPS (ttm)
-1.58
Balance Sheet and Cash Flow
Total Cash (mrq)
133.09M
Total Debt/Equity (mrq)
141.69%
Levered Free Cash Flow (ttm)
-70.25M
Research Analysis: LQDA
View MoreCompany Insights: LQDA
LQDA does not have Company Insights
Research Reports: LQDA
View MoreDaily – Vickers Top Buyers & Sellers for 04/20/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/16/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/28/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/22/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.